Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma (Olmesartan Medoxomil, Amlodipine, Hydrochlorothiazide)

Olmesartan medoxomil, amlodipine and hydrochlorothiazide, the active ingredients in Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma, are a combination antihypertensive presented as a tablet for oral use. They are indicated for the management of hypertension in adult patients. The formulation combines an angiotensin II receptor blocker, a calcium‑channel blocker, and a thiazide diuretic to achieve synergistic blood‑pressure reduction.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable logistics for global distribution.

Olmesartán/Amlodipino/Hidroclorotiazida Kern Pharma is used to treat hypertension by targeting multiple pathways that regulate blood pressure. - Essential hypertension: lowers systolic and diastolic blood pressure. - Secondary hypertension: provides additive control when monotherapy is insufficient. - Hypertensive patients with fluid retention: combines diuretic effect to reduce volume overload.

Olmesartán/Amlodipino/Hidroclorotiazida may cause a range of adverse reactions, varying from mild to severe. Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Peripheral edema: swelling of ankles or feet. - Flushing: transient warmth and redness. - Fatigue: feeling of tiredness. Serious or Rare Side Effects: - Angioedema: rapid swelling of face, lips or airway requiring emergency care. - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte disturbances: significant potassium or sodium imbalance. - Renal impairment: sudden decrease in kidney function.

Before initiating therapy, several safety considerations should be evaluated. - Blood pressure monitoring: check baseline and periodic readings to assess efficacy. - Renal function assessment: evaluate serum creatinine and eGFR before and during treatment. - Electrolyte surveillance: monitor potassium and sodium levels, especially with the diuretic component. - Pregnancy and lactation: use only if benefits outweigh risks, as safety data are limited. - Concomitant medications: review for potential interactions that may affect blood pressure or renal function. - Store at room temperature: keep tablets in the original pack, protect from moisture and light.

Olmesartán/Amlodipino/Hidroclorotiazida can interact with several drug classes, requiring careful management. Major Interactions (Avoid): - Aliskiren: combined use with olmesartan may increase risk of renal impairment and hypotension. - Potassium‑sparing diuretics or supplements: may cause hyperkalaemia. - Lithium: increased lithium levels and toxicity. - NSAIDs: can reduce antihypertensive effect and worsen renal function. Moderate Interactions (Monitor Closely): - ACE inhibitors: additive effect on potassium and renal function; monitor labs. - Beta‑blockers: may enhance blood‑pressure lowering; watch for bradycardia. - CYP3A4 inhibitors (e.g., erythromycin): may increase amlodipine concentrations.